Recent news on Novoseven

Novo Nordisk Reports 1Q Profit Growth  -  May 2, 2007
Forbes,The Denmark-based company said modern insulin sales grew 32 percent and sales of blood clotting agent NovoSeven rose 12 percent.

Novo Nordisk Announces Financial Statement for First Quarter 2007  -  May 2, 2007
PR Newswire (press release),Sales of NovoSeven(R) increased by 12% (18% in local currencies). -- Sales of Norditropin(R) increased by 11% (16% in local currencies).

Citigroup Downgrades Novo Nordisk  -  May 3, 2007
Forbes,...profit to $300 million, or 94 cents per share, as modern insulin sales grew 32 percent and sales of blood clotting agent NovoSeven rose 12 percent.

GTC Biotherapeutics Reports First Quarter 2007 Financial Results  -  May 3, 2007
PharmaLive.com (press release),...worldwide market for rhFVIIa could be $2 billion by 2012, which is the year when the patents on the current marketed product, NovoSeven(R), expire.

Danish shares close higher, led up by Novozymes; Bang & Olufsen ...  -  Apr 25, 2007
ABCmoney.co.uk,...not seek regulatory approval for its NovoSeven drug to treat intracerebral haemorrhage, Gudme Raaschou said, adding there is no room for disappointment.

Danish shares close higher, led up by Novozymes; Bang & Olufsen ...  -  Apr 25, 2007
ABCmoney.co.uk,...not seek regulatory approval for its NovoSeven drug to treat intracerebral haemorrhage, Gudme Raaschou said, adding there is no room for disappointment.

Healthy Shot For Your Portfolio  -  Apr 4, 2007
Forbes,Its NovoSeven treatment for bleeding episodes in people with hemophilia has shown excellent growth. The company's Norditropin growth hormone has also been a

Pills For Your Ills, But Not The Ones You Think  -  Mar 28, 2007
Scienceline,Approved to treat bleeding in hemophilia patients, doctors are using NovoSeven off-label to treat hemorrhages – a use that has been linked to increased risk

Novo Nordisk Still Sees NovoSeven Sales Up 10 Pct  -  Mar 19, 2007
Reuters.uk,CO: Quote, Profile , Research) still expects sales of its drug NovoSeven to climb 10 percent this year despite a recent regulatory setback for the

Phase 3 stroke trial shows that NovoSeven® reduces bleeding in the ...  -  Feb 27, 2007
PipelineReview.com (press release),Announced the initial results of a phase 3 clinical trial investigating NovoSeven® (recombinant activated factor VII) for the treatment of people suffering

Novo Nordisk releases third phase clinical trial of NovoSeven  -  Feb 26, 2007
Prdomain Business Register (press release),26 Feb 2007 : Novo Nordisk today announced the initial results of a phase 3 clinical trial investigating NovoSeven® (recombinant activated factor VII) for

Novo Nordisk won't seek clearance for NovoSeven for bleeding in ...  -  Feb 26, 2007
Forbes,COPENHAGEN (AFX) - Novo Nordisk AS said it has decided not to apply for regulatory approval for its NovoSeven product to treat intracerebral haemorrhage

Novo Nordisk drops NovoSeven for brain haemorrhage  -  Feb 26, 2007
Pharma Times (subscription),Denmark's Novo Nordisk says that it has decided not to seek regulatory approval for its drug NovoSeven to treat bleeding in the brain, on the back of

UPDATE 1-Nordisk drops NovoSeven for brain haemorrhage  -  Feb 26, 2007
ReutersCO: Quote, Profile , Research) said on Monday it had decided not to seek regulatory approval for its drug NovoSeven to treat bleeding in the brain,

Roche Ending Maxygen Deal For Factor VII Over De-Risk'  -  Mar 14, 2007
BioWorld Online,The deal-breaking differences with Maxygen take place against a background of not only the safety controversy over NovoSeven, the strong-selling Factor VII

No Dice for Novo  -  Feb 28, 2007
Motley FoolShares of drugmaker Novo Nordisk (NYSE: NVO) were down more than 5% yesterday after it announced that a phase 3 label expanding study of coagulant NovoSeven

Novo Nordisk Drug Fails Trial  -  Feb 26, 2007
TheStreet.comAs a result, Novo Nordisk won't seek regulatory approval for the drug NovoSeven as a treatment for people suffering from bleeding on the brain called

No go for Novo's potential stroke therapy  -  Feb 28, 2007
DrugResearcher.com,A Phase III clinical trial of coagulation therapy NovoSeven showed that although the drug reduced the amount of bleeding in the brains of patients suffering

Novo Nordisk Drug Doesn't Improve Stroke Survival (Update3)  -  Feb 26, 2007
BloombergInitial results from late-stage testing showed that NovoSeven didn't reduce the instances of severe disability or death as it subdued bleeding in the brains

Novo Nordisk Reports Disappointing Results from Phase III Trial in ...  -  Feb 26, 2007
Genetic Engineering News (press release),Novo Nordisk released results of a Phase III trial investigating NovoSeven® (recombinant activated factor VII) for the treatment of people suffering from

Danish shares close lower, led down by Novo Nordisk; Danisco ...  -  Feb 26, 2007
Forbes,COPENHAGEN (AFX) - Share prices closed lower, led down by Novo Nordisk on news it has decided not to apply for regulatory approval for its NovoSeven product

Danish shares lower midmorning; Novo Nordisk sharply lower  -  Feb 26, 2007
Forbes,...'The news from Novo Nordisk on NovoSeven is having a negative effect on the market and that will probably be the case for the whole day,' a broker said.

Danish shares close lower, led down by AP Moeller-Maersk, Novo ...  -  Feb 27, 2007
Forbes,...which extended yesterday's fall after it said it would not proceed with registration of NovoSeven for treatment of brain bleeding, brokers said.

Triple whammy for European drugs highlights risk  -  Feb 26, 2007
Reuters Italia,But the day's heaviest losses were recorded by Novo Nordisk, a smaller Danish firm, which tumbled 7 percent after abandoning plans to sell NovoSeven as a

Triple whammy for European drugs highlights risk  -  Feb 26, 2007
ReutersCO: Quote, Profile, Research), a smaller Danish firm, which tumbled 7 percent after abandoning plans to sell NovoSeven as a treatment for brain haemorrhage

Danish shares AFX market data at 9.25 am Novo Nordisk sharply lower  -  Feb 26, 2007
Forbes,The group said it will not seek regulatory approval for its NovoSeven drug to treat intracerebral haemorrhage (ICH), or bleeding in the brain,

GTC Biotherapeutics Reports Fourth Quarter and Year End 2006 ...  -  Mar 5, 2007
Business Wire (press release),...total worldwide market for rhFVIIa will be $2 billion by 2012, which is the year when the patents on the current marketed product, NovoSeven ® , expire.

GTC Biotherapeutics Reports Fourth Quarter and Year End 2006 ...  -  Mar 5, 2007
Genetic Engineering News (press release),...total worldwide market for rhFVIIa will be $2 billion by 2012, which is the year when the patents on the current marketed product, NovoSeven(R), expire.

Danish shares close lower, led down by FLSmidth, TrygVesta UPDATE  -  Feb 28, 2007
Forbes,...with a reduced target price of 500 dkr from 530 dkr after the 'disappointing' phase III data on the use of NovoSeven in strokes, dealers said.

Danish shares sharply lower midmorning  -  Feb 27, 2007
Forbes,Novo Nordisk (nyse: NVO - news - people ) fell 14.50 dkr to 470.50, following the group's statement yesterday it will not use its drug NovoSeven for

European Stocks Climb on Commodity Prices; BP, BHP, Rio Advance  -  Feb 26, 2007
BloombergThe company said it won't seek to register blood-clotting drug NovoSeven to treat strokes after data showed it didn't improve patients' recovery.

Euroshares gain midday as M&A news, Dow futures lift the mood  -  Feb 26, 2007
Forbes,And shares in Novo Nordisk slumped 6.63 pct after the pharmaceutical group announced it will not seek regulatory approval for use of its drug NovoSeven for

Danish shares sharply lower midmorning  -  Feb 27, 2007
ABCmoney.co.uk,Novo Nordisk fell 14.50 dkr to 470.50, following the group's statement yesterday it will not use its drug NovoSeven for bleeding in the brain, Krogh Nielsen

European Markets Rise On Strong Oils, Miners - European Commentary  -  Feb 26, 2007
Trading Markets,Novo Nordisk, the world's largest insulin maker, dropped 5.4% after the company said it won't seek to register blood-clotting drug NovoSeven to treat

Persimmon, AB Foods Lead FTSE Higher  -  Feb 26, 2007
123Jump.com,Danish drugmaker Novo Nordisk fell 7.5% after the company said it was not seeking regulatory approval to treat bleeding on the brain with NovoSeven after

Oils lift European shares near new 6-year high  -  Feb 26, 2007
FXstreet.com The Foreign Exchange Market,Still in the sector, Danish drugmaker Novo Nordisk fell 7.7 percent after saying it will not seek regulatory approval for its NovoSeven drug to treat

Novo Nordisk's NovoSeven has potential for 14 bln dkr sales by ...  -  Feb 1, 2007
Forbes,COPENHAGEN (AFX) - Novo Nordisk A/S's bleeding inhibition drug NovoSeven may have the potential to create cumulative sales of 14 bln dkr by 2015 if it is

TECHNOLOGY TRADER  -  Feb 11, 2007
Barron's (subscription)A second, more speculative prospect for Novo is the use of its hemophilia drug NovoSeven in bleeding-trauma patients and in heart surgery.

Use of Recombinant Factor VIIa for Hip Surgery in a Patient with ...  -  Feb 1, 2007
Journal of Bone and Joint Surgery (subscription)Recombinant activated factor VII (recombinant factor VIIa) (NovoSeven; Novo Nordisk, Bagsvaerd, Denmark) was approved by the United States Food and Drug

Novo increased profit by 10 per cent  -  Feb 8, 2007
Copenhagen Capacity,The sale of the bleeder drug Novoseven increased by 11 per cent to a total sale of DKK 5.6 billion. - We are very satisfied with the achieved results for

Solid full-year 2006 results for Denmark's Novo Nordisk  -  Jan 31, 2007
Pharma Times (subscription),Among the major products in Novo's biopharmaceuticals business, sales of which climbed 12% to 10.88 billion kroner, NovoSeven (recombinant Factor VIIa) was

Business News  -  Jan 31, 2007
Danmark.dk,Novo's treatment for haemophiliacs, Novoseven, accounted for total sales of DKK 5.6 billion. The North American market in particular helped to jazz up the

Danish shares close higher, led up by Jyske Bank, DS Torm UPDATE  -  Feb 6, 2007
Forbes,...people ) as saying Novo Nordisk's drug NovoSeven could double its present sales of 6 bln dkr if it gets accepted for treatment of critical bleeding.

Danish shares close higher, led up by Jyske Bank, DS Torm UPDATE  -  Feb 6, 2007
ABCmoney.co.uk,Novo Nordisk B rose 5 to 518 after daily Boersen cited Citigroup as saying Novo Nordisk's drug NovoSeven could double its present sales of 6 bln dkr if it

Novo Nordisk Q4 pretax higher on strong sales of key products - UPDATE  -  Jan 31, 2007
Forbes,Sales of Biopharmaceuticals grew 7.4 pct to 2.907 bln dkr, with sales of the biggest product NovoSeven, growing 5.8 pct to 1.470 bln dkr.

Novo Nordisk Announces Financial Statement for 2006  -  Jan 31, 2007
CNW Telbec (Communiqués de presse),Reported sales increased by 15% in 2006 (local currency growth of 16%) - Sales of modern insulins (insulin analogs) increased by 48% - Sales of NovoSeven(R)

Decreased Bleeding Frequency With Secondary Prophylactic Use Of ...  -  26 Dec 2006
Medical News Today (press release),Data presented at the 48th Annual Meeting of the American Society of Hematology (ASH) from a study testing the use of NovoSeven® Coagulation Factor VIIa

Soldiers' Families Question Army's Use of Controversial Drug  -  26 Dec 2006
ABC News...they'd given him Factor VII," says Lufkin, referring to Recombinant Activated Factor VIIa — or rF7a, sold as NovoSeven — a blood-clotting medication.

ABC NEWS Medical Unit  -  26 Dec 2006
ABC NewsRecombinant Factor VIIa — or rF7a, sold as NovoSeven — is a blood-clotting medication approved by the FDA only to control bleeding episodes in some

Dealing with uncontrolled bleeding  -  Nov 29, 2006
Hindu,That drug is NovoSeven (Recombinant Factor VIIa or rFVIIa), made by Nodo Norvisk, the Danish parmaceuticals company. It has only been licensed foruse with

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional